A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

NCT02371629 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

776

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: NVA237
DRUG: Placebo
DRUG: Salbutamol

Sponsor

Novartis Pharmaceuticals